Anti-CD20 antibody (mAb) represents an effective strategy for the treatment of B cell
malignancies, possibly involving complement activity, antibody-dependent cellular
cytotoxicity and phagocytosis (ADP). While ADP by Kupffer cells deplete circulating tumors,
mechanisms targeting non-circulating tumors remain unclear. Using intravital imaging in a
model of B cell lymphoma, we establish here the dominance and limitations of ADP in the
bone marrow (BM). We found that tumor cells were stably residing in the BM with little …

Anti-CD20 monoclonal antibody (mAb) represents an effective strategy for the treatment of B
cell malignancies that may involve complement activity, antibody dependent cellular
cytotoxicity (ADCC) and phagocytosis (ADP). While ADP mediated by Kupffer cells is
essential to deplete circulating tumors, the relative contribution of each mechanism to the
elimination of non-circulating targets has yet to be clarified. Using intravital imaging in a
model of MYC-driven B cell lymphoma, we establish here the dominance and limitations of …